US equities
|
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Cyclo Therapeutics, Inc. - Common Stock
(NQ:
CYTH
)
0.7206
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 25, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cyclo Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals
March 26, 2025
Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the...
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results
March 13, 2025
From
Rafael Holdings, Inc.
Via
GlobeNewswire
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
February 20, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)
February 07, 2025
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025
January 14, 2025
From
Cyclo Therapeutics, Inc.
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USAP, FLIC, ARCH, CYTH on Behalf of Shareholders
December 16, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, ARCH, CYTH on Behalf of Shareholders
December 14, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results
December 11, 2024
Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™
From
Rafael Holdings, Inc.
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENLC, ALVR, CYTH on Behalf of Shareholders
December 10, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USAP, CYTH, ARCH on Behalf of Shareholders
December 05, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 14, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
November 06, 2024
Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical need
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
October 21, 2024
Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience
From
Pacira BioSciences
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)
September 06, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
September 05, 2024
From
Cyclo Therapeutics
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, ARCH, CYTH on Behalf of Shareholders
August 27, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)
August 27, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
August 26, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, SDIG, ARCH, CYTH on Behalf of Shareholders
August 24, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
CYTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cyclo Therapeutics, Inc. Is Fair to Shareholders
August 22, 2024
From
Halper Sadeh LLC
Via
Business Wire
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
August 22, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
August 22, 2024
From
Rafael Holdings, Inc.; Cyclo Therapeutics
Via
GlobeNewswire
Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 15, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer’s Disease from European Patent Office
July 29, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
June 25, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
June 14, 2024
Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
May 30, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 16, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 18, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
March 14, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
